Refill non-adherence to repeat prescriptions leads to treatment gaps or to high extra costs

Pharmacy World and Science

Volumn 29, Issue 1, 2007, Pages 19-24

  Krigsman, Kristin ^a   Melander, Arne ^a,b   Carlsten, Anders ^c   Ekedahl, Anders ^c   Nilsson, J Lars G ^a  

^a Network for Pharmacoepidemiology Foundation   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Apoteket AB   (Sweden)

Author keywords

Costs; Exemption from charges; Oversupply; Refill adherence; Repeat prescriptions; Treatment gaps; Undersupply

Indexed keywords

ARTICLE; CALCULATION; COST BENEFIT ANALYSIS; DRUG COST; DRUG PACKAGING; DRUG USE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; SWEDEN; TREATMENT REFUSAL;

AMBULATORY CARE; COSTS AND COST ANALYSIS; HUMANS; PATIENT COMPLIANCE; PHARMACEUTICAL PREPARATIONS; PHARMACIES; PRESCRIPTIONS, DRUG; SWEDEN; TREATMENT REFUSAL;

EID: 33847153070     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-005-4797-8     Document Type: Article

References (27)

1. World Health Organization. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003 ISBN 924 154599 2
2. Andersson K, Melander A, Svensson C, Lind O, Nilsson JLG Repeat prescriptions - refill adherence in relation to patient and prescriber characteristics, reimbursement level and type of medication. Eur J Public Health 2005 Dec; 15(6):621-626
3. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity and applications. J Clin Epidemiol 1997; 50:105-116
4. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288(4):462-467
5. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow-up study. Heart 2002; 88:229-233
6. Morningstar BA, Sketris IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002; 27:213-220
7. Mojtabai R, Lavelle J, Gibson PJ, Sohler NL, Craig TJ, Carlson GA et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr Serv 2002; 53:337-339
8. Hylan TR, Dunn RL, Tepner RG, Meurgey F. Gaps in antidepressant prescribing in primary care in the United Kingdom. Int Clin Psychopharmacol 1998; 13(6):235-243
9. Rudd P, Ramesh J, Bryant-Kosling C, Guerrero D. Gaps in cardiovascular medication taking: the tip of the iceberg. J Gen Intern Med 1993; 8(12):659-666
10. Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R (2001) Interventions for helping patients to follow prescriptions for medications. (Cochrane Review). In: The Cochrane Library, Issue 3, Oxford: Update Software
11. Heaton PC, Cluxton RJ, Moomaw CJ. Acetaminophen oversupply in the Ohio medicaid population. J Am Pharm Assoc 2003; 43:680-684
12. Frediani F, Cannata AP, Magnoni A, Peccarisi C, Bussone G. The patients with medication oversupply: clinical management problems. Neurol Sci 2003; 24(Suppl 2):108-111
13. Noyce PR, Huttin C, Atella V, Brenner G, Haaijer-Ruskamp FM, Hedvall M-B et al. The cost of prescription medicines to patients. Health Policy 2000; 52:129-145
14. LIF (Läkemedelsindustriföreningen), Fakta (2004) Pharmaceutical market and healthcare. LIF, Stockholm
15. Schafheutle EI, Hassell K, Noyce PR, Weiss MC. Access to medicines: cost as an influence on the views and behaviour of patients. Health Soc Care Commun 2002; 10:187-195
16. O'Brien B. The effect of patient charges on the utilisation of prescription medicines. J Health Econ 1989; 8(1):109-132
17. Lundberg L, Johannesson M, Isacson D, Borgquist L. Effect of user charges on the use of prescription medicines in different socio-economic groups. Health Policy 1998; 44:123-134
18. Westerlund T, Almarsdóttir AB, Melander A. Drug-related problems and pharmacy interventions in community practice. Int J Pharm Pract 1999; 7:40-50
19. (1997) Medical products agency, Vol. 10, §37-38. Sweden LVFS, Uppsala. ISSN 1101-5225
20. Al-Saffar N, Deshmukh A, Eid S, Carter P. Health beliefs and drug compliance of depressed patients in Kuwait. J Soc Adm Pharm 2003; 20:142-150
21. Apoteket AB (2002) Annual report, p. 42. Apoteket AB, Stockholm
22. Morris LS, Schulz RM. Patient compliance - an overview. J Clin Pharm Therap 1992; 17:283-295
23. George CF, Peveler RC, Heiliger S, Thompson C. Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Pharm 2000; 50:166-171
24. Casado JL, Sabido R, Perez-Elias MJ, Antela A, Oliva J, Dronda F et al. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients. Antivir Ther 1999; 4(3):157-161
25. Information obtained from the drug statistics database of Apoteket AB, Stockholm
26. Isacson D, Olofsson C. Drugs up in smoke: a study of caseated drugs in Sweden. Pharm World Sci 1999; 21(2):96-99
27. Ekedahl A, Wergeman L, Rydberg T. Unused drugs in Sweden measured by returns to pharmacies. J Soc Adm Pharm 2003; 20:26-31